Femasys (NASDAQ:FEMY) Price Target Cut to $8.00 by Analysts at Chardan Capital

Femasys (NASDAQ:FEMY) had its target price reduced by stock analysts at Chardan Capital from $10.00 to $8.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Femasys in a report on Tuesday.

Femasys Price Performance

NASDAQ:FEMY opened at $0.98 on Wednesday. The firm has a market capitalization of $21.79 million, a price-to-earnings ratio of -1.27 and a beta of -2.83. The company has a debt-to-equity ratio of 0.43, a current ratio of 6.47 and a quick ratio of 5.93. The business has a 50 day simple moving average of $1.16 and a 200-day simple moving average of $1.15. Femasys has a 1 year low of $0.73 and a 1 year high of $2.40.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 120.13%. Equities analysts forecast that Femasys will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Femasys

An institutional investor recently bought a new position in Femasys stock. Aljian Capital Management LLC bought a new position in shares of Femasys Inc. (NASDAQ:FEMY) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned about 0.11% of Femasys at the end of the most recent quarter. 65.27% of the stock is currently owned by institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.